openPR Logo
Press release

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017

07-03-2018 05:59 AM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline

The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.

Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market

As per the findings of research, it was found that most of the IPF drug candidates target chemokine receptor. The analysis was also done based on route of administration and it was found that major drug candidates are being developed to be administered by oral route.

Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market/report-sample

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. The drug candidate of MediciNova, Inc. has been granted Orphan Drug Designation for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and others.

About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research-based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017 here

News-ID: 1106647 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Arthritis Therapeutics Pipeline Analysis, Clinical Trials & Results, Patent and Developments
Arthritis Therapeutics Pipeline Analysis, Clinical Trials & Results, Patent and …
Arthritis is an inflammatory disorder that occurs in joints and surrounding tissues. There are six types of arthritis namely osteoarthritis, autoimmune arthritis, psoriatic arthritis, juvenile arthritis, gout arthritis, and infectious arthritis. Symptoms of arthritis can include pain, swelling, redness, stiffness and decrease in movement. Some of the risk factors associated with arthritis are aging, obesity, joint injury, and family history. Certain laboratory tests such as blood test, and urine test,

All 5 Releases


More Releases for IPF

Idiopathic Pulmonary Fibrosis (IPF) Market Size, Share, Industry, Forecast and o …
Idiopathic Pulmonary Fibrosis (IPF) Market Global Idiopathic Pulmonary Fibrosis (IPF) Market Set for Remarkable Growth, Projected to Reach US$ 4,614.3 Million by 2030 The global Idiopathic Pulmonary Fibrosis (IPF) market, valued at US$ 2,184.4 million in 2022, is poised for substantial expansion, with projections reaching up to US$ 4,614.3 million by 2030. Anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 10.1% during the forecast period from 2024 to 2031, the
Breath of Hope: IPF Drug Pipeline Landscape (2022)
Market Outlook: Breath of Hope: IPF Drug Pipeline Landscape (2022) The IPF Drug Pipeline Landscape embarks on a transformative journey, offering a breath of hope for individuals grappling with Idiopathic Pulmonary Fibrosis (IPF). This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to reshape the trajectory of IPF treatment over the next decade. Market Drivers: Precision Therapies on the Horizon: At the forefront of the IPF Drug Pipeline, the prospect of
Idiopathic Pulmonary Fibrosis (IPF) Market to Reach US$ 6,825.3 Million by 2033 …
The newly published report by IMARC Group, titled "Idiopathic Pulmonary Fibrosis (IPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the idiopathic pulmonary fibrosis (IPF) market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor
Recent Release: Global Idiopathic pulmonary fibrosis (IPF) Market To 2023
MarketResearchReports.Biz presents this most up-to-date research on "Idiopathic pulmonary fibrosis (IPF)- Epidemiology Forecast To 2023" Idiopathic pulmonary fibrosis (IPF) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Idiopathic pulmonary fibrosis (IPF) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Idiopathic pulmonary fibrosis (IPF) prevalent or incident cases segmented by age, sex and
Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel Advancement for the Treatm …
The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF. Browse the Report Summary at: www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market Insights on pipeline segments As per the findings of research, it was found
Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market F …
DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. DelveInsight expertise has expanded from an initial focus on Pipeline & Marketed Reports to Market Forecasting and Epidemiology Reports. Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology